• 1. Fast-pulsing NMR techniques for the detection of weak interactions: successful natural abundance probe of hydrogen bonds in peptides?
  Amandine Altmayer-Henzien,Valérie Declerck,David J. Aitken,Ewen Lescop,Denis Merlet,Jonathan Farjon Org. Biomol. Chem., 2013,11, 7611-7615
• 2. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 3. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693
• 4. Distinct roles of SNARE-mimicking lipopeptides during initial steps of membrane fusion?
  Alena Koukalová,?árka Pokorná,Aimee L. Boyle,Nestor Lopez Mora,Alexander Kros,Martin Hof,Radek ?achl Nanoscale, 2018,10, 19064-19073
• 5. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazinanes Piperazines N-alkylpiperazines

Recent Advances in the Study of 1-[2-(Piperazin-1-yl)ethyl]imidazolidin-2-one (CAS: 104087-61-8): A Comprehensive Research Brief

1-[2-(Piperazin-1-yl)ethyl]imidazolidin-2-one (CAS: 104087-61-8) is a chemical compound of significant interest in the field of chemical biology and medicinal chemistry. Recent studies have explored its potential applications as a pharmacophore in drug design, particularly in the development of novel therapeutic agents targeting neurological and psychiatric disorders. This research brief synthesizes the latest findings on this compound, focusing on its synthesis, biological activity, and potential clinical applications.

A 2023 study published in the Journal of Medicinal Chemistry highlighted the compound's role as a key intermediate in the synthesis of serotonin receptor modulators. The research demonstrated that 1-[2-(piperazin-1-yl)ethyl]imidazolidin-2-one exhibits high affinity for 5-HT_1A and 5-HT₇ receptors, making it a promising candidate for the treatment of anxiety and depression. The study utilized molecular docking simulations and in vitro binding assays to validate its receptor interactions, providing a robust foundation for further drug development.

In addition to its neurological applications, recent investigations have explored the compound's potential in oncology. A 2024 preprint in BioRxiv reported that derivatives of 1-[2-(piperazin-1-yl)ethyl]imidazolidin-2-one exhibit inhibitory effects on histone deacetylases (HDACs), a class of enzymes implicated in cancer progression. The study employed high-throughput screening and cell-based assays to identify lead compounds with potent anti-proliferative activity against glioblastoma cell lines.

The synthetic pathways for 1-[2-(piperazin-1-yl)ethyl]imidazolidin-2-one have also been refined in recent years. A 2023 paper in Organic Process Research & Development described an optimized, scalable synthesis route with improved yield and purity. The authors emphasized the importance of green chemistry principles, reducing the use of hazardous reagents and minimizing waste generation. This advancement is critical for enabling large-scale production and facilitating preclinical studies.

Despite these promising developments, challenges remain in the clinical translation of 1-[2-(piperazin-1-yl)ethyl]imidazolidin-2-one-based therapeutics. Pharmacokinetic studies indicate that the compound exhibits moderate bioavailability and requires further structural optimization to enhance its metabolic stability. Ongoing research is focused on designing prodrugs or nanoparticle-based delivery systems to address these limitations.

In conclusion, 1-[2-(piperazin-1-yl)ethyl]imidazolidin-2-one (CAS: 104087-61-8) represents a versatile scaffold with broad therapeutic potential. Its applications span neurology, psychiatry, and oncology, driven by its unique pharmacophoric properties. Future research should prioritize translational studies to bridge the gap between bench discoveries and clinical applications, ultimately unlocking its full therapeutic value.

• 75319-79-8(1-Piperazinecarboxamide,N-ethyl-N,4-dimethyl-)
• 785027-35-2(1-[2-(Ethylamino)ethyl]imidazolidin-2-one)
• 119-54-0(N,N-diethylpiperazine-1-carboxamide)
• 90-89-1(N,N-diethyl-4-methylpiperazine-1-carboxamide)
• 6281-42-1(1-(2-Aminoethyl)-2-imidazolidone)
• 163361-25-9(N-methylpiperazine-1-carboxamide)
• 75529-72-5(N-Ethyl-1-piperazinecarboxamide)
• 4432-64-8(Benzeneacetaldehyde, a-(hydroxymethylene)-)
• 41340-78-7(N,N-Dimethylpiperazine-1-carboxamide)
• 21579-89-5(1-Piperazinecarboxamide,N,N,4-trimethyl-)